NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HS-22-002 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-087 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-049 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Funding Opportunity PA-22-048 from the NIH Guide for Grants and Contracts. Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB)
Funding Opportunity PA-22-047 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for grant funding to conduct Large Research Projects (R01) focused on Combating Antibiotic-Resistant Bacteria (CARB) .
Notice NOT-OD-22-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-22-106 from the NIH Guide for Grants and Contracts. Adolescents have some of the poorest outcomes along the HIV care continuum around the world. Differentiated care or differentiated service delivery has great promise to meet the needs of adolescents living with HIV and reduce unnecessary burdens on the healthcare system. Differentiated care or differentiated service delivery is defined as client-centered approaches that simplify and adapt HIV services across the care continuum, in ways that both better serve the needs of adolescents living with HIV and reduce unnecessary burdens on the health system. Most of the data on differentiated care has been limited to ART delivery for stable adults in high-prevalence settings in sub-Saharan Africa. A recent supplement to the Journal of the International AIDS Society on differentiated care and HIV provides data to support these new approaches to providing care to PLHIV; however, programs rarely target the unique needs of ALWH.
Notice NOT-DA-21-085 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-009 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-072 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-063 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) solicits applications for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). The target population(s) should include individuals from underrepresented racial/ethnic (R/E) minority populations. Applicants should address cancer health disparities (CHD) through a network of local multidisciplinary and integrated partners that include community health educators (CHEs), lay health advisors (LHAs), community members, healthcare providers, and researchers working in coordination to educate and refer R/E minority populations to NCI-supported CTs, and increase awareness in providers about R/E minority participation in NCI clinical trials. This will require outreach and education multilevel interventions at the CT site, provider, and/or patient levels. The proposed interventions should be informed by relevant theories, frameworks, or models and guided by preliminary data and/or the sufficient infrastructure in place and expertise on the local contextual barriers and facilitators for increasing CT referral of R/E minority population. It is expected that U01 grantees will establish partnerships with the community, primary care providers, and other stakeholders to enhance identification of R/E minority referral barriers and facilitators to NCI-supported CTs. A companion funding opportunity (see U24 funding opportunity RFA-CA-21-058) will support a Data, Evaluation and Coordinating Center (DECC) that will provide experienced project
Funding Opportunity PAR-21-347 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIMHD R25 program is to support educational activities that enhance the diversity of the clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences.
Notice NOT-ES-22-002 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-046 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-016 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-032 from the NIH Guide for Grants and Contracts
Notice NOT-TW-21-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-075 from the NIH Guide for Grants and Contracts. To expand our understanding of protozoan parasite persistence mechanisms and provide research tools and strategies to enable identification and credentialing of novel treatments for persistent protozoan pathogens.
Funding Opportunity RFA-MH-22-105 from the NIH Guide for Grants and Contracts. Adolescents have some of the poorest outcomes along the HIV care continuum around the world. Differentiated care or differentiated service delivery has great promise to meet the needs of adolescents living with HIV and reduce unnecessary burdens on the healthcare system. Differentiated care or differentiated service delivery is defined as client-centered approaches that simplify and adapt HIV services across the care continuum, in ways that both better serve the needs of adolescents living with HIV and reduce unnecessary burdens on the health system. Most of the data on differentiated care has been limited to ART delivery for stable adults in high-prevalence settings in sub-Saharan Africa. A recent supplement to the Journal of the International AIDS Society on differentiated care and HIV provides data to support these new approaches to providing care to PLHIV; however, programs rarely target the unique needs of ALWH.
Funding Opportunity RFA-MH-22-125 from the NIH Guide for Grants and Contracts. This initiative encourages research focused on development of and testing the effectiveness of intervention approaches that utilize enhanced interpersonal strategies to strengthen and compliment efforts in suicide prevention. Existing suicide prevention practices emphasize safety management protocols and intrapersonal coping skills but tend to focus less on strategies addressing interpersonal targets that contribute to suicide risk. The intent of this initiative is to develop and/or utilize interpersonal treatment strategies that reduce risk by enhancing perceived social supports and connections that contribute to life-affirming beliefs, intentions, and behaviors, in ways consistent with conceptual models of suicide risk, to enhance the effectiveness of existing evidence-based treatments and develop new approaches, as indicated.